Ironwood Pharmaceuticals (IRWD) EBIT (2010 - 2026)

Ironwood Pharmaceuticals has disclosed EBIT across 17 years of filings, most recently posting $72.6 million for Q1 2026.

• EBIT for Q1 2026 came in at $72.6 million, up 349.32% year-over-year; the trailing twelve-month figure through Mar 2026 was $116.4 million (up 119.61% YoY), and the FY2025 annual result was $14.7 million, down 84.21% from the prior year.
• EBIT came in at $72.6 million for Q1 2026 at Ironwood Pharmaceuticals, up from -$77.0 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $75.5 million in Q3 2025 to a low of -$1.1 billion in Q2 2023.
• The 5-year median for EBIT is $37.6 million (2023), against an average of -$41.9 million.
• Across the five-year window, EBIT tumbled 2046.17% in 2023 and soared 349.32% in 2026, its largest moves.
• Ironwood Pharmaceuticals' EBIT stood at -$129.0 million in 2022, then jumped by 129.15% to $37.6 million in 2023, then decreased by 16.22% to $31.5 million in 2024, then slumped by 344.49% to -$77.0 million in 2025, then soared by 194.26% to $72.6 million in 2026.
• The last three EBIT figures came in at $72.6 million (Q1 2026), -$77.0 million (Q4 2025), and $75.5 million (Q3 2025), per Business Quant data.